Hutchmed (China)
HCM
14.28
-0.32
-2.19%
Hutchmed (China)
US · HCM
#2639 by market cap
Listed 2016
14.28
-0.32
-2.19%
Live - 5344 symbols - heartbeat 47s ago
· 2026-10-08 04:18
Pre-market
13.95
-2.31%
After-hours
14.28
0.00%
Overnight
14.30
+0.14%
- Market cap
- 2.49B
- P/E (TTM)i
- 178.50
- P/Bi
- 1.98
- EPSi
- 2.60
- Div yieldi
- 0.00%
- 52W posi
- 69%
Reader sentiment
Are you bullish or bearish on HCM?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.78, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -12.96% YoY
Margins
- Gross margin
- 38.68%
- Operating margin
- -6.51%
- Net margin
- 83.30%
Key ratios & quality
- Enterprise valuei
- 1.22B
- Altman Z-Scorei
- 3.78
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 214.11M | 204.89M | 227.98M | 356.13M | 426.41M | 838.00M | 630.20M | 548.51M |
| Gross profit | 70.17M | 44.74M | 39.46M | 97.89M | 115.31M | 453.55M | 281.32M | 212.16M |
| Selling & admin expenses | 48.65M | 52.93M | 61.35M | 127.13M | 136.11M | 133.18M | 112.91M | 103.03M |
| Research & development | 78.82M | 91.94M | 174.78M | 299.09M | 386.89M | 302.00M | 212.11M | 148.30M |
| Operating profit | -92.64M | -146.39M | -196.67M | -328.00M | -406.26M | 21.51M | -40.61M | -35.70M |
| Pretax profit | -86.66M | -141.11M | -189.73M | -215.74M | -410.42M | 58.31M | -1.11M | 498.69M |
| Tax | 3.96M | 3.27M | 4.83M | 11.92M | -283.00K | 4.51M | 7.19M | 63.61M |
| Net profit | -71.29M | -103.68M | -115.52M | -167.04M | -360.39M | 101.09M | 38.17M | 457.73M |
| Basic EPS | -1 | -1 | -1 | -1 | -2 | 1 | 0 | 3 |
| Diluted EPS | -0.55 | -0.80 | -0.90 | -1.25 | -2.15 | 0.60 | 0.20 | 2.65 |
| Line item | 2023-12 | 2024-06 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | -- | -- | -- | -- | -- | -- |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | -- | -- | -- | -- | -- | -- |
| Pretax profit | -- | -- | -- | -- | -- | -- |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -- | -- | -- | -- | -- | -- |
| Basic EPS | -- | -- | -- | -- | -- | -- |
| Diluted EPS | -- | -- | -- | -- | -- | -- |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 370.54M | 317.02M | 530.74M | 1.21B | 839.89M | 1.10B | 1.07B | 1.57B |
| Cash & ST investments | 300.95M | 217.17M | 435.18M | 1.01B | 631.00M | 886.34M | 836.11M | 1.37B |
| Inventory | 12.31M | 16.21M | 19.77M | 35.76M | 56.69M | 50.26M | 50.40M | 41.13M |
| Total assets | 532.12M | 465.12M | 724.12M | 1.37B | 1.03B | 1.28B | 1.27B | 1.75B |
| Total current liabilities | 85.48M | 113.10M | 158.40M | 311.66M | 353.90M | 403.03M | 376.56M | 315.78M |
| Short-term debt | 0 | 3.22M | 0 | 26.91M | 3.71M | 35.08M | 26.30M | 27.85M |
| Long-term debt | 26.74M | 26.82M | 26.86M | 0 | 18.10M | 48.19M | 59.43M | 68.19M |
| Total liabilities | 119,863,000.00 | 152,219,000.00 | 205,169,000.00 | 333,147,000.00 | 392,575,000.00 | 536,386,000.00 | 502,343,000.00 | 501,835,000.00 |
| Total equity | 412.26M | 312.90M | 518.95M | 1.04B | 636.87M | 743.39M | 771.85M | 1.25B |
| Retained earnings | -183.00M | -289.73M | -415.59M | -610.33M | -971.48M | -870.87M | -833.17M | -378.64M |
| Line item | 2023-12 | 2024-06 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.10B | 1.05B | 1.07B | 1.59B | 1.57B | 1.55B |
| Cash & ST investments | 886.34M | 802.45M | 836.11M | 1.36B | 1.37B | 1.37B |
| Inventory | 50.26M | 46.44M | 50.40M | -- | 41.13M | 40.84M |
| Total assets | 1.28B | 1.26B | 1.27B | 1.78B | 1.75B | 1.74B |
| Total current liabilities | 403.03M | 373.29M | 376.56M | 342.41M | 315.78M | 275.21M |
| Short-term debt | 35.08M | 26.47M | 26.30M | -- | 27.85M | 22.41M |
| Long-term debt | 48.19M | 55.63M | 59.43M | 93.44M | 68.19M | 72.10M |
| Total liabilities | 536,386,000.00 | 508,850,000.00 | 502,343,000.00 | 534,017,000.00 | 501,835,000.00 | 461,459,000.00 |
| Total equity | 743.39M | 752.02M | 771.85M | 1.24B | 1.25B | 1.27B |
| Retained earnings | -870.87M | -845.07M | -833.17M | -- | -378.64M | -362.72M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -32.85M | -80.91M | -62.07M | -204.22M | -268.60M | 219.26M | 497.00K | -64.66M |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- | -- | -- |
| Free cash flow | -39.21M | -89.48M | -83.97M | -220.98M | -305.26M | 186.65M | -17.44M | -88.81M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -1.58M | -95.00K | 306.03M | 690.01M | -47.91M | -3.98M | -35.27M | 1.58M |
| Ending cash balance | 86.04M | 121.16M | 235.63M | 377.54M | 313.28M | 283.59M | 153.96M | 71.33M |
| Line item | 2023-12 | 2024-06 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -- | -- | -- | -- | -- | -- |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | -- | -- | -- | -- | -- | -- |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | -- | -- | -- | -- | -- | -- |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -17.59 | -31.32 | -32.57 | -26.46 | -45.18 | 15.03 | 5.06 | 45.74 |
| ROA %i | -13.24 | -21.26 | -21.14 | -18.57 | -30.04 | 8.73 | 2.95 | 30.19 |
| ROIC %i | -17.36 | -29.58 | -30.34 | -25.41 | -44.70 | 9.75 | 1.18 | 38.06 |
| 5-year avg ROE %i | -25.11 | -21.12 | -16.20 | -23.24 | -30.62 | -24.10 | -16.82 | -1.16 |
| EBIT margin %i | -40.00 | -68.37 | -82.88 | -60.41 | -96.10 | 7.05 | 0.28 | 91.44 |
| FCF / sales %i | -- | -- | -- | -- | -- | 22.27 | -- | -- |
| Current ratioi | 4.33 | 2.80 | 3.35 | 3.89 | 2.37 | 2.72 | 2.83 | 4.96 |
| Quick ratioi | 4.12 | 2.54 | 3.08 | 3.67 | 2.14 | 2.57 | 2.67 | 4.79 |
| Debt / assetsi | 5.03 | 7.11 | 4.55 | 2.48 | 2.62 | 6.73 | 7.05 | 5.58 |
| LT debt / equityi | 6.87 | 10.37 | 6.80 | 0.73 | 3.82 | 6.99 | 8.36 | 5.66 |
| Interest coveragei | -84.88 | -136.00 | -240.09 | -363.43 | -628.48 | 77.82 | 0.61 | 175.06 |
| Revenue CAGR (3Y) %i | 6.31 | -1.76 | -1.86 | 18.48 | 27.67 | 54.33 | 20.96 | 8.76 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2023-12 | 2024-06 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 15.03 | -5.51 | 5.06 | 47.42 | 45.74 | 1.44 |
| ROA %i | 8.73 | -3.28 | 2.95 | 30.75 | 30.19 | 1.02 |
| ROIC %i | 9.75 | -5.02 | 1.18 | 44.08 | 38.06 | 1.32 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 7.05 | -13.12 | 0.28 | 4.28 | 91.44 | 92.14 |
| FCF / sales %i | 22.27 | -- | -- | -- | -- | 1.81 |
| Current ratioi | 2.72 | 2.81 | 2.83 | 4.65 | 4.96 | 5.64 |
| Quick ratioi | 2.57 | 2.66 | 2.67 | 4.41 | 4.79 | 5.45 |
| Debt / assetsi | 6.73 | 6.51 | 7.05 | 5.26 | 5.58 | 5.44 |
| LT debt / equityi | 6.99 | 7.52 | 8.36 | 7.60 | 5.66 | 5.72 |
| Interest coveragei | 77.82 | -- | 0.61 | -- | 175.06 | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Oncology/Immunology is the largest reported line at 52.06% of revenue, across 2 reported segments.
- Other Ventures follows at 47.94%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Oncology/Immunology52.06%
Other Ventures47.94%
Region
People’s Republic of China (PRC)74.28%
US and Others25.72%
Quote time 2026-10-08 04:18:46 · For reference only, not investment advice and not tailored to your situation.